Concentration System.

The studies (study codes: SH-Nen-0016 and SH-Nen-0017) were conducted in accordance of rights with the Resolve of Helsinki and were approved by the philosophy administrative unit of the Body of Uppsala and by the Swedish Medical Products Government agency. Written informed consent was received from all subjects prior to status. The studies were performed at Quintiles AB, Uppsala, Sweden.
All subjects underwent a full clinical interrogation, physical inquiring and electrocardiogram (ECG) at pre-entry. A testing ground display for haematology and serum biochemistry was performed prior to enrolment, on day 7 of each artistic style geological period, and 5-7 days after the last subject area day.
The two studies were conducted according to a randomised, open, three-way crosswalk creativity. Each of the trio tending periods lasted for 7 days, which was sufficient to achieve steady province. The subjects received either oral doses of an eso- meprazole 40mg ballistic capsule once daily (studies A and B), a naproxen 250mg pill twice daily (study A), a rofecoxib 12.5mg pill once daily (study B), or esomeprazole in sequence with naproxen (study A) or rofecoxib (study B).